/PRNewswire/ VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5.
VolitionRx (NYSE-A:VNRX) Limited revealed that it has been awarded a further $1.5 million in non-dilutive funding from Namur Invest Capital Risk in Belgium..
Share this article
Share this article
AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ VolitionRx Limited (NYSE AMERICAN: VNRX) ( Volition ) today announced it has been awarded additional non-dilutive funding totaling approximately $4 million from the Walloon Region and Namur Invest, Belgium. To date, Agencies from the Walloon Region have awarded Volition an aggregate of approximately $13 million in non-dilutive funding including this most recent award. This additional funding consisted of a cash grant of $1.3 million and $2.7 million in loans. It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash at favorable terms to support the Company s continued development, and this latest funding takes the total non-dilutive funding to-date from all sources to over $15 million, commented Cameron Reynolds, President and Chief Executive Officer of Volition. Mr. Reynolds added, We are delighted with the great progress we are making on s